Myrcludex B is an experimental drug for the treatment of hepatitis B and D. The first Phase IIa clinical trials with 40 patients concluded in 2014, finding that the drug was well tolerated and, as far as can be said with the limited data, effective against hepatitis B.
Mechanism of action
The hepatitis B virus uses its surface lipopeptide pre-S1 for docking to mature liver cells via their sodium/bile acid cotransporter (NTCP) and subsequently entering the cells. Myrcludex B is a synthetic N-acylated pre-S1 that can also dock to NTCP, blocking the virus's entry mechanism.
The drug is also effective against hepatitis D because the hepatitis D virus is only infective in the presence of a hepatitis B virus infection.
- Spreitzer, H (14 September 2015). "Neue Wirkstoffe – Myrcludex B". Österreichische Apothekerzeitung (in German) (19/2015): 12.
- "New Medical Therapies for Hepatitis B". CenterWatch. 27 October 2014.
- Volz, T; Allweiss, L; Ben Mbarek, M; Warlich, M; Lohse, A. W.; Pollok, J. M.; Alexandrov, A; Urban, S; Petersen, J; Lütgehetmann, M; Dandri, M (May 2013). "The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus". J Hepatol. 58 (5): 861–867. doi:10.1016/j.jhep.2012.12.008. PMID 23246506.
- Abbas, Zaigham; Abbas, M (August 2015). "Management of hepatitis delta: Need for novel therapeutic options". World J Gastroenterol. 21 (32): 9461–9465. doi:10.3748/wjg.v21.i32.9461. PMC 4548107. PMID 26327754.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|